A Phase 3 interventional study of flortaucipir F 18 in Alzheimer Disease, sponsored by Avid Radiopharmaceuticals. Completed at 1 site in United States. Per ClinicalTrials.gov, last updated 2020-09-09.
Sponsored by Avid Radiopharmaceuticals (part of Eli Lilly and Company) · Phase 3, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing flortaucipir in Alzheimer Disease — 4 open to participants now, 4 under way, none of them phase 3. flortaucipir · Alzheimer Disease.
Among the 22 studies testing flortaucipir in Alzheimer Disease, this one is the 3rd largest by enrollment, is one of 3 that started in 2019, is one of 3 in phase 3, and was the 18th registered.
3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →4 of the 22 studies testing flortaucipir in Alzheimer Disease are open now, in 2 countries. Recruiting first, the newest first:
Eli Radiopharma · Sites in China
Ages 50–85 · Healthy volunteers
University of Alabama at Birmingham · Sites in United States
Ages 50+ · Healthy volunteers
Mayo Clinic · Sites in United States
Ages 60+ · Women only · Healthy volunteers
Mayo Clinic · Sites in United States
Ages 21–80
By country, each count listing its studies:
flortaucipir: first EMA approval 2024. What it is approved for, and how studies give it, is on its page →
Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 7 · Phase 3 4 · Phase 4 1
First in 2013; this study’s year is marked. 3 started in 2019.
This study's enrollment of 242 is above the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 70 across the 22 interventional studies. Of the 17 that completed or were terminated, 15 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 22 have an industry lead sponsor. The 6 most frequent:
This study is registered under Avid Radiopharmaceuticals, one of the names counted as Eli Lilly and Company. Under that name alone:
Avid Radiopharmaceuticals is the lead sponsor of 54 studies on the registry; none are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 10 (91%) have results posted.
99 studies in Alzheimer Disease by Eli Lilly and Company: 13 open now, 19 under way, 8 of them phase 3. Of 79 finished, 61 (77%) have results posted.
Among the 99 studies in Alzheimer Disease by Eli Lilly and Company, this one is the 24th largest by enrollment of the 95 interventional ones that give a count, is one of 2 that started in 2019, is one of 24 in phase 3, and was the 72nd registered.
Eli Lilly and Company’s Alzheimer Disease studies by the year they started, since 2002.
2 of the studies testing flortaucipir in Alzheimer Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07580703Eli RadiopharmaA Phase I Study of [18F]Flortaucipir PET Imaging in Chinese Subjects: Safety, Pharmacokinetics, Biodistribution, Radiation Dosimetry, and Preliminary Diagnostic Efficacy | 2026-12-31 |
| NCT02740634Mayo ClinicMolecular and Structural Imaging in Alzheimer's Disease: A Longitudinal Study | 2027-03 |
Add all 2 to your calendar (.ics) → With an account.
Among the 22 studies testing flortaucipir in Alzheimer Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 99 in Alzheimer Disease:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the performance of physician readers trained to read flortaucipir-PET (positron emission tomography) scans.
Scan Reader Criteria (5 total):
Scan Criteria:
Scan Study Population Criteria for FR01 (A05 confirmatory cohort):
Scan Study Population Criteria for FR01 (Study A16):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Scans previously acquired from Study A16 (NCT02516046) and A05 (NCT02016560) will be read by independent, blinded readers.
Drug: flortaucipir F 18
No study drug will be administered.
Also known as: 18F-AV-1451, [F-18]T807, LY3191748
Primary Objective 1 Analysis 1: Diagnostic Performance of Individual Readers (NFT Score)
Sensitivity and specificity of 5 independent readers' interpretations of ante-mortem 18F-AV-1451 PET imaging for detection of a pattern of 18F-AV-1451 neocortical uptake that corresponds to neurofibrillary tangles (NFT) Score of B3 (Hyman et al., 2012; Montine et al., 2012). NFT B scores range from B0 (no NFTs in the brain) to B3 (widespread NFTs in the brain). Sensitivity and specificity are percentages that can range from 0 to 100%. The hypothesis tested was that, of the 5 independent imaging physicians, at least 3 will have the lower bounds of 2-sided 95% CIs ≥50%, for both sensitivity and specificity.
Time frame: baseline scan
Primary Objective 1 Analysis 2: Diagnostic Performance of Individual Readers (NIA-AA Autopsy Diagnosis)
Sensitivity and specificity of 5 independent readers' interpretations of ante-mortem 18F-AV-1451 PET imaging for detection of a pattern of 18F-AV-1451 neocortical uptake that corresponds to high levels of AD neuropathologic change (High ADNC) as defined by National Institute on Aging-Alzheimer's Association (NIA-AA) criteria (see Hyman et al. 2012). ADNC categories are None, Low, Intermediate and High, with High indicating the most severe level of AD-related pathology changes in the brain. The hypothesis tested was that, of the 5 independent imaging physicians, at least 3 will have the lower bounds of 2-sided 95% CIs ≥50%, for both sensitivity and specificity.
Time frame: baseline scan
Primary Objective 2: Inter-reader Reliability of Reader Interpretation of Flortaucipir-PET Imaging
As measured by Fleiss' Kappa across all scans read. Fleiss' kappa is a statistical measure for assessing the reliability of agreement between a fixed number of raters when assigning categorical ratings to a number of items or classifying items. Fleiss' kappa can range from 0 to 1 with 1 indicating perfect agreement between the readers. Scan results binarized as positive AD pattern versus negative AD pattern. Results are displayed as percentage of agreement for individual reader pairs, computed as follows: number of images for which reader had the same interpretation divided by the total number of images evaluated, multiplied by 100%.
Time frame: baseline scan
Secondary Objective 1 Analysis 1: Diagnostic Performance of τAD++ Flortaucipir PET Images to Detect B3 NFTs
Flortaucipir F 18 PET imaging will be classified by each reader as either neocortical uptake not consistent with AD (τAD-), neocortical uptake consistent with AD (τAD+), or neocortical uptake consistent with AD with uptake beyond the temporal/occipital regions (τAD++). NFT scoring is according to Hyman, et al 2012. Truth positive is a NFT B3 score. Truth negative is NFT \<B3 score.
Time frame: baseline scan
Secondary Objective 1 Analysis 2: Diagnostic Performance of τAD++ Flortaucipir PET Images to Detect High ADNC
Sensitivity and specificity of 5 independent readers' interpretations of ante-mortem 18F-AV-1451 PET imaging for detection of a pattern of 18F-AV-1451 neocortical uptake that corresponds to high levels of AD neuropathologic change (High ADNC) as defined by National Institute on Aging-Alzheimer's Association (NIA-AA) criteria (Hyman et al. 2012). Truth positive is a High ADNC score. Truth negative is No/Low/Intermediate ADNC score.
Time frame: baseline scan
Secondary Objective 2: Inter-reader Reliability of Reader Interpretation of τAD++ Flortaucipir PET Images
Overall reader agreement as measured by Fleiss' Kappa statistic. Scan results binarized as τAD++ versus τAD+/τAD-. Results are displayed as percentage of agreement for individual reader pairs, computed as follows: number of images for which reader had the same interpretation divided by the total number of images evaluated, multiplied by 100%.
Time frame: baseline scan
Secondary Objective 3: Inter-reader Reliability of Flortaucipir PET Scan Interpretation in the Population of Intended Use
Reader agreement measured by Fleiss' Kappa across scans from non-autopsy cases from Study A05. Scan results binarized as positive for AD pattern versus negative for AD pattern. Results are displayed as percentage of agreement for individual reader pairs, computed as follows: number of images for which reader had the same interpretation divided by the total number of images evaluated, multiplied by 100%.
Time frame: baseline scan
Secondary Objective 4: Intra-reader Reliability of Reader Interpretation of Flortaucipir-PET Imaging
Cohen's Kappa will be calculated for each of 5 readers to assess the intra-reader reliability of flortaucipir F 18 PET scan visual interpretation. The statistic takes into account the possibility of the agreement occurring by chance. Cohen's kappa values range from 0 to 1 with 1 representing perfect agreement. Results are displayed as percentage of agreement within a reader, computed as follows: number of images for which reader had the same interpretation at initial and second read divided by the total number of images evaluated twice by a reader, multiplied by 100%.
Time frame: baseline scan
Subjects were not recruited for this study. Study scans were selected from 2 previously completed imaging studies. Scans previously acquired from Study A16 (NCT02516046) and A05 (NCT02016560) were read by 5 independent, blinded to other study information.
| Milestone | All Autopsy Cases | Non-Autopsy Cases |
|---|---|---|
| Started | 83 | 159 |
| Completed | 83 | 159 |
| Not completed | 0 | 0 |
Sensitivity and specificity of 5 independent readers' interpretations of ante-mortem 18F-AV-1451 PET imaging for detection of a pattern of 18F-AV-1451 neocortical uptake that corresponds to neurofibrillary tangles (NFT) Score of B3 (Hyman et al., 2012; Montine et al., 2012). NFT B scores range from B0 (no NFTs in the brain) to B3 (widespread NFTs in the brain). Sensitivity and specificity are percentages that can range from 0 to 100%. The hypothesis tested was that, of the 5 independent imaging physicians, at least 3 will have the lower bounds of 2-sided 95% CIs ≥50%, for both sensitivity and specificity.
| percentage of cases correctly identified | Sensitivity of Flortaucipir vs Autopsy NFT Score | Specificity of Flortaucipir vs Autopsy NFT Score |
|---|---|---|
| Reader 1 | 91.5 (80.07 to 96.64) | 77.1 (60.98 to 87.93) |
| Reader 2 | 89.4 (77.41 to 95.37) | 91.4 (77.62 to 97.04) |
| Reader 3 | 87.2 (74.83 to 94.02) | 85.7 (70.62 to 93.74) |
| Reader 4 | 93.6 (82.84 to 97.81) | 62.9 (46.34 to 76.83) |
| Reader 5 | 89.4 (77.41 to 95.37) | 77.1 (60.98 to 87.93) |
Sensitivity and specificity of 5 independent readers' interpretations of ante-mortem 18F-AV-1451 PET imaging for detection of a pattern of 18F-AV-1451 neocortical uptake that corresponds to high levels of AD neuropathologic change (High ADNC) as defined by National Institute on Aging-Alzheimer's Association (NIA-AA) criteria (see Hyman et al. 2012). ADNC categories are None, Low, Intermediate and High, with High indicating the most severe level of AD-related pathology changes in the brain. The hypothesis tested was that, of the 5 independent imaging physicians, at least 3 will have the lower bounds of 2-sided 95% CIs ≥50%, for both sensitivity and specificity.
| percentage of cases correctly identified | Sensitivity of Flortaucipir vs NIA-AA Autopsy Diagnosis | Specificity of Flortaucipir vs NIA-AA Autopsy Diagnosis |
|---|---|---|
| Reader 1 | 95.1 (83.86 to 98.65) | 70.7 (55.52 to 82.39) |
| Reader 2 | 95.1 (83.86 to 98.65) | 85.4 (71.56 to 93.12) |
| Reader 3 | 95.1 (83.86 to 98.65) | 82.9 (68.74 to 91.47) |
| Reader 4 | 97.6 (87.40 to 99.57) | 58.5 (43.37 to 72.24) |
| Reader 5 | 95.1 (83.86 to 98.65) | 73.2 (58.07 to 84.31) |
As measured by Fleiss' Kappa across all scans read. Fleiss' kappa is a statistical measure for assessing the reliability of agreement between a fixed number of raters when assigning categorical ratings to a number of items or classifying items. Fleiss' kappa can range from 0 to 1 with 1 indicating perfect agreement between the readers. Scan results binarized as positive AD pattern versus negative AD pattern. Results are displayed as percentage of agreement for individual reader pairs, computed as follows: number of images for which reader had the same interpretation divided by the total number of images evaluated, multiplied by 100%.
| percentage agreement of cases | All Cases |
|---|---|
| Reader 1 v Reader 2 | 95.0 |
| Reader 1 v Reader 3 | 93.4 |
| Reader 1 v Reader 4 | 94.6 |
| Reader 1 v Reader 5 | 97.1 |
| Reader 2 v Reader 3 | 97.1 |
| Reader 2 v Reader 4 | 91.3 |
| Reader 2 v Reader 5 | 94.6 |
| Reader 3 v Reader 4 | 91.3 |
| Reader 3 v Reader 5 | 93.8 |
| Reader 4 v Reader 5 | 95.0 |
Flortaucipir F 18 PET imaging will be classified by each reader as either neocortical uptake not consistent with AD (τAD-), neocortical uptake consistent with AD (τAD+), or neocortical uptake consistent with AD with uptake beyond the temporal/occipital regions (τAD++). NFT scoring is according to Hyman, et al 2012. Truth positive is a NFT B3 score. Truth negative is NFT \<B3 score.
| percentage cases correctly identified | Sensitivity of Flortaucipir tAD++ vs Autopsy NFT Score | Specificity of Flortaucipir tAD++ vs Autopsy NFT Score |
|---|---|---|
| Reader 1 | 87.2 (74.83 to 94.02) | 88.6 (74.05 to 95.46) |
| Reader 2 | 80.9 (67.46 to 89.58) | 100.0 (90.11 to 100.00) |
| Reader 3 | 76.6 (62.78 to 86.40) | 94.3 (81.39 to 98.42) |
| Reader 4 | 89.4 (77.41 to 95.37) | 82.9 (67.32 to 91.90) |
| Reader 5 | 83.0 (69.86 to 91.11) | 94.3 (81.39 to 98.42) |
Sensitivity and specificity of 5 independent readers' interpretations of ante-mortem 18F-AV-1451 PET imaging for detection of a pattern of 18F-AV-1451 neocortical uptake that corresponds to high levels of AD neuropathologic change (High ADNC) as defined by National Institute on Aging-Alzheimer's Association (NIA-AA) criteria (Hyman et al. 2012). Truth positive is a High ADNC score. Truth negative is No/Low/Intermediate ADNC score.
| percentage of cases correctly identified | Sensitivity | Specificity |
|---|---|---|
| Reader 1 | 92.7 (80.57 to 97.48) | 82.9 (68.74 to 91.47) |
| Reader 2 | 85.4 (71.56 to 93.12) | 92.7 (80.57 to 97.48) |
| Reader 3 | 85.4 (71.56 to 93.12) | 92.7 (80.57 to 97.48) |
| Reader 4 | 92.7 (80.57 to 97.48) | 75.6 (60.66 to 86.17) |
| Reader 5 | 87.8 (74.46 to 94.68) | 87.8 (74.46 to 94.68) |
Overall reader agreement as measured by Fleiss' Kappa statistic. Scan results binarized as τAD++ versus τAD+/τAD-. Results are displayed as percentage of agreement for individual reader pairs, computed as follows: number of images for which reader had the same interpretation divided by the total number of images evaluated, multiplied by 100%.
| percentage agreement of cases | All Cases |
|---|---|
| Reader 1 v Reader 2 | 92.5 |
| Reader 1 v Reader 3 | 90.0 |
| Reader 1 v Reader 4 | 91.3 |
| Reader 1 v Reader 5 | 95.0 |
| Reader 2 v Reader 3 | 91.7 |
| Reader 2 v Reader 4 | 90.5 |
| Reader 2 v Reader 5 | 94.2 |
| Reader 3 v Reader 4 | 88.8 |
| Reader 3 v Reader 5 | 92.5 |
| Reader 4 v Reader 5 | 92.9 |
Reader agreement measured by Fleiss' Kappa across scans from non-autopsy cases from Study A05. Scan results binarized as positive for AD pattern versus negative for AD pattern. Results are displayed as percentage of agreement for individual reader pairs, computed as follows: number of images for which reader had the same interpretation divided by the total number of images evaluated, multiplied by 100%.
| percentage agreement of cases | A05 Cases |
|---|---|
| Reader 1 v Reader 2 | 97.5 |
| Reader 1 v Reader 3 | 93.1 |
| Reader 1 v Reader 4 | 95.6 |
| Reader 1 v Reader 5 | 97.5 |
| Reader 2 v Reader 3 | 93.1 |
| Reader 2 v Reader 4 | 94.3 |
| Reader 2 v Reader 5 | 96.2 |
| Reader 3 v Reader 4 | 93.7 |
| Reader 3 v Reader 5 | 93.1 |
| Reader 4 v Reader 5 | 96.9 |
Cohen's Kappa will be calculated for each of 5 readers to assess the intra-reader reliability of flortaucipir F 18 PET scan visual interpretation. The statistic takes into account the possibility of the agreement occurring by chance. Cohen's kappa values range from 0 to 1 with 1 representing perfect agreement. Results are displayed as percentage of agreement within a reader, computed as follows: number of images for which reader had the same interpretation at initial and second read divided by the total number of images evaluated twice by a reader, multiplied by 100%.
| percentage agreement of cases | Randomly Selected Re-reads |
|---|---|
| Reader 1 | 95.0 |
| Reader 2 | 85.0 |
| Reader 3 | 80.0 |
| Reader 4 | 95.0 |
| Reader 5 | 90.0 |
Collected over Not applicable. Adverse events were not assessed during this study.. Non-serious events are listed at a 0.5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| All Cases | — | — | — |
| Age, Continuous(years) | All Cases |
|---|---|
| Study A16 Autopsy Cases | 81.6 ± 9.91 |
| Study A05 Non-autopsy Cases | 72.9 ± 9.64 |
| Sex: Female, Male(Participants) | All Cases |
|---|---|
| Study A16 Autopsy Cases — Female | 41 |
| Study A16 Autopsy Cases — Male | 42 |
| Study A05 Non-autopsy Cases — Female | 74 |
| Study A05 Non-autopsy Cases — Male | 85 |
| Ethnicity (NIH/OMB)(Participants) | All Cases |
|---|---|
| Study A16 Autopsy Cases — Hispanic or Latino | 4 |
| Study A16 Autopsy Cases — Not Hispanic or Latino | 79 |
| Study A16 Autopsy Cases — Unknown or Not Reported | 0 |
| Study A05 Non-autopsy Cases — Hispanic or Latino | 9 |
| Study A05 Non-autopsy Cases — Not Hispanic or Latino | 150 |
| Study A05 Non-autopsy Cases — Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | All Cases |
|---|---|
| Study A16 Autopsy Cases — American Indian or Alaska Native | 0 |
| Study A16 Autopsy Cases — Asian | 1 |
| Study A16 Autopsy Cases — Native Hawaiian or Other Pacific Islander | 0 |
| Study A16 Autopsy Cases — Black or African American | 1 |
| Study A16 Autopsy Cases — White | 81 |
| Study A16 Autopsy Cases — More than one race | 0 |
| Study A16 Autopsy Cases — Unknown or Not Reported | 0 |
| Study A05 Non-autopsy Cases — American Indian or Alaska Native | 0 |
| Study A05 Non-autopsy Cases — Asian | 2 |
| Study A05 Non-autopsy Cases — Native Hawaiian or Other Pacific Islander | 0 |
| Study A05 Non-autopsy Cases — Black or African American | 3 |
| Study A05 Non-autopsy Cases — White | 154 |
| Study A05 Non-autopsy Cases — More than one race | 0 |
| Study A05 Non-autopsy Cases — Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2019 to primary completion in Apr 2019, 1 month.
Results were first posted in Aug 2020, 1 year 3 months after primary completion. A results delay was requested in Jan 2020.
Of 75 industry-sponsored phase 3 interventional studies under Alzheimer Disease, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 61. This study's 1 month is below that.
Counting every sponsor, half of 101 studies reached it within 47 months; a quarter within 28 and three quarters within 73.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Flortaucipir